Redesign Science Raises $15M to Advance Computational Structure-Based Drug Discovery
Summary
Using state-of-the-art physics-based simulation algorithms, Redesign Science has successfully identified early hits for several emerging and challenging target classes, ranging from precision cancer therapeutics to first-in-class small molecules for inflammatory bowel disease. "We are rethinking both the computational infrastructure and core algorithms to not only scale up the scope and accuracy of virtual screening, but also the pace of actionable scientific discovery," Haotian Li, cofounder and CTO. With proceeds from the recent financings, Redesign will expand its cloud computing infrastructure and advance several core screening algorithms to scale across a diverse range of biological target classes. Redesign will continue to advance strategic co-development partnerships with leading biotech firms and will launch an internal pipeline of early stage asset development. Redesigns mission is to use cutting edge computational approaches to better understand protein dynamics for precision structure-based drug discovery and to expand the druggable proteome.